Profitability Metrics

Gross Margin
93.85%
Operating Margin
67.81%
Net Margin
57.02%

Efficiency Metrics

Revenue per Expense Ratio
1.61
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
67.81%
Income Tax Rate
0.27%
EPS
5.0800000000

Balance Sheet Analysis

Current Ratio
2.24
Cash Ratio
58.55
Working Capital
$457.96K
Debt to Equity
0.33
Debt to Assets
23.15%
Equity Ratio
69.41%

Cash Flow Analysis

Operating Cash Flow Ratio
18.47%
Free Cash Flow Ratio
18.47%
CapEx to Revenue
0.00%
Dividends Paid
$30.31M
Stock Buybacks
$3.73M
Total Shareholder Returns
$34.04M
Cash Position Change
104,790,400.0%

Key Takeaways (2023 FY)

  • Revenue declined by 23.969002712194%, indicating potential market challenges
  • Increased dividend payments by 22.93%

Detailed Growth Metrics

Core Performance

Revenue
-23.97%
Net Income
-55.63%
EPS
-55.16%
Operating Income
-48.27%

Operational Efficiency

R&D Expenses
-100.00%
SG&A Expenses
87.99%
Operating Cash Flow
634.04%
Free Cash Flow
634.04%

Balance Sheet Health

Assets
6.46%
Debt
8.58%
Book Value per Share
7.74%
Inventory
-35.73%

Shareholder Returns

Dividends per Share
22.93%
Shares Outstanding
-1.01%

Long Term Trends

3Y Revenue/Share
135.72%
5Y Revenue/Share
1,017.28%
3Y Dividend/Share
8.34%
5Y Dividend/Share
-35.74%